Cargando…

Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current

Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies...

Descripción completa

Detalles Bibliográficos
Autores principales: Hernández-Bule, María Luisa, Martínez, María Antonia, Trillo, María Ángeles, Martínez, Lidia, Toledano-Macías, Elena, Úbeda, Alejandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488331/
https://www.ncbi.nlm.nih.gov/pubmed/34630714
http://dx.doi.org/10.3892/ol.2021.13068
_version_ 1784578142039441408
author Hernández-Bule, María Luisa
Martínez, María Antonia
Trillo, María Ángeles
Martínez, Lidia
Toledano-Macías, Elena
Úbeda, Alejandro
author_facet Hernández-Bule, María Luisa
Martínez, María Antonia
Trillo, María Ángeles
Martínez, Lidia
Toledano-Macías, Elena
Úbeda, Alejandro
author_sort Hernández-Bule, María Luisa
collection PubMed
description Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies have demonstrated that subthermal CRET currents can elicit a number of cell responses, including anti-proliferative effects, in the human liver cancer cell line HepG2. Such effects involve significant changes in the regulation of proteins involved in MAPK signaling pathways, which are also implicated in the cancer cell response to standard anticancer drugs such as sorafenib. This overlap in response pathways may lead to competitive, neutralizing or blocking interactions between the electrical and chemical treatments, thus raising questions on the advisability of CRET treatment for their analgesic, anti-inflammatory or other purposes in patients undergoing chemotherapy. The present study analyzed the effects of simultaneous treatment with sorafenib and 448-kHz, subthermal CRET current on the proliferation and viability of HepG2 cell cultures. Cell viability was assessed through Trypan blue or XTT assays, while flow cytometry was applied for cell cycle and apoptosis analysis. The expression of proteins involved in cell proliferation were assessed by immunoblotting and immunofluorescence. The results revealed no evidence to suggest that the electrical treatment counteracted or neutralized the cellular response to sorafenib at the different conditions evaluated. Furthermore, at the standard pharmacological sorafenib concentration, 5 µM, the combined treatment elicited an anti-proliferative response significantly stronger than that induced by each of the treatments when applied separately in HepG2 cells. These data do not support the hypothesis that CRET exposure may inhibit or diminish the effects of a chemotherapeutic drug used in cancer treatment, and highlights the requirement for further investigation into the cell response to the combined action of electrical and chemical treatments.
format Online
Article
Text
id pubmed-8488331
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-84883312021-10-07 Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current Hernández-Bule, María Luisa Martínez, María Antonia Trillo, María Ángeles Martínez, Lidia Toledano-Macías, Elena Úbeda, Alejandro Oncol Lett Articles Due to their alleged analgesic, anti-inflammatory and tissue regenerative effects, capacitive-resistive electrothermal therapy (CRET), which is based on non-invasive exposure to radiofrequency (RF) currents, is often applied to chemotherapeutically treated patients with cancer. Our previous studies have demonstrated that subthermal CRET currents can elicit a number of cell responses, including anti-proliferative effects, in the human liver cancer cell line HepG2. Such effects involve significant changes in the regulation of proteins involved in MAPK signaling pathways, which are also implicated in the cancer cell response to standard anticancer drugs such as sorafenib. This overlap in response pathways may lead to competitive, neutralizing or blocking interactions between the electrical and chemical treatments, thus raising questions on the advisability of CRET treatment for their analgesic, anti-inflammatory or other purposes in patients undergoing chemotherapy. The present study analyzed the effects of simultaneous treatment with sorafenib and 448-kHz, subthermal CRET current on the proliferation and viability of HepG2 cell cultures. Cell viability was assessed through Trypan blue or XTT assays, while flow cytometry was applied for cell cycle and apoptosis analysis. The expression of proteins involved in cell proliferation were assessed by immunoblotting and immunofluorescence. The results revealed no evidence to suggest that the electrical treatment counteracted or neutralized the cellular response to sorafenib at the different conditions evaluated. Furthermore, at the standard pharmacological sorafenib concentration, 5 µM, the combined treatment elicited an anti-proliferative response significantly stronger than that induced by each of the treatments when applied separately in HepG2 cells. These data do not support the hypothesis that CRET exposure may inhibit or diminish the effects of a chemotherapeutic drug used in cancer treatment, and highlights the requirement for further investigation into the cell response to the combined action of electrical and chemical treatments. D.A. Spandidos 2021-11 2021-09-23 /pmc/articles/PMC8488331/ /pubmed/34630714 http://dx.doi.org/10.3892/ol.2021.13068 Text en Copyright: © Hernández-Bule et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Articles
Hernández-Bule, María Luisa
Martínez, María Antonia
Trillo, María Ángeles
Martínez, Lidia
Toledano-Macías, Elena
Úbeda, Alejandro
Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title_full Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title_fullStr Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title_full_unstemmed Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title_short Response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
title_sort response of human cancer cells to simultaneous treatment with sorafenib and radiofrequency current
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488331/
https://www.ncbi.nlm.nih.gov/pubmed/34630714
http://dx.doi.org/10.3892/ol.2021.13068
work_keys_str_mv AT hernandezbulemarialuisa responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent
AT martinezmariaantonia responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent
AT trillomariaangeles responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent
AT martinezlidia responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent
AT toledanomaciaselena responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent
AT ubedaalejandro responseofhumancancercellstosimultaneoustreatmentwithsorafenibandradiofrequencycurrent